Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hafner

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
AIDS (London, England)|April 24, 2001
Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDSJ M Jacobson, R Hafner, J Remington, et al.
Antimicrobial Agents and Chemotherapy|April 17, 2001
Tolerance and pharmacokinetic interactions of rifabutin and azithromycinR Hafner, J Bethel, H C Standiford, et al.
AIDS (London, England)|November 1, 1996
Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. ANRS 005/ACTG 154 Trial GroupF Derouin, C Leport, S Pueyo, et al.
Chemical Communications (Cambridge, England)|September 23, 2020
Fatty acids as biomimetic replication agents for luminescent metal-organic framework patternsMichael R Hafner, Francesco Carraro, Lea A Brandner, et al.
The American Journal of Clinical Nutrition|April 8, 2006
Association between dietary fiber and serum C-reactive proteinYunsheng Ma, Jennifer A Griffith, Lisa Chasan-Taber, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|April 15, 1997
Survival after AIDS-defining events in patients with < 200 lymphocytes CD4+ x 10(6)/L who are toxoplasmosis antibody positive. ANRS 005/ACTG 154 Trial GroupS Pueyo, L R Salmi, G Chêne, et al.
Environmental Science & Technology|September 30, 2006
Particulate matter: A strategic vision for transportation-related researchMichael C McCarthy, Douglas S Eisinger, Hilary R Hafner, et al.
Antimicrobial Agents and Chemotherapy|March 28, 1998
Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteersR Hafner, J Bethel, M Power, et al.
American Journal of Respiratory and Critical Care Medicine|October 6, 1997
Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study GroupR Hafner, J A Cohn, D J Wright, et al.
The New England Journal of Medicine|April 15, 2000
Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDSW M El-Sadr, W J Burman, L B Grant, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
AIDS (London, England)|April 24, 2001
Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDSJ M Jacobson, R Hafner, J Remington, et al.
Antimicrobial Agents and Chemotherapy|April 17, 2001
Tolerance and pharmacokinetic interactions of rifabutin and azithromycinR Hafner, J Bethel, H C Standiford, et al.
AIDS (London, England)|November 1, 1996
Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. ANRS 005/ACTG 154 Trial GroupF Derouin, C Leport, S Pueyo, et al.
Chemical Communications (Cambridge, England)|September 23, 2020
Fatty acids as biomimetic replication agents for luminescent metal-organic framework patternsMichael R Hafner, Francesco Carraro, Lea A Brandner, et al.
The American Journal of Clinical Nutrition|April 8, 2006
Association between dietary fiber and serum C-reactive proteinYunsheng Ma, Jennifer A Griffith, Lisa Chasan-Taber, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|April 15, 1997
Survival after AIDS-defining events in patients with < 200 lymphocytes CD4+ x 10(6)/L who are toxoplasmosis antibody positive. ANRS 005/ACTG 154 Trial GroupS Pueyo, L R Salmi, G Chêne, et al.
Environmental Science & Technology|September 30, 2006
Particulate matter: A strategic vision for transportation-related researchMichael C McCarthy, Douglas S Eisinger, Hilary R Hafner, et al.
Antimicrobial Agents and Chemotherapy|March 28, 1998
Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteersR Hafner, J Bethel, M Power, et al.
American Journal of Respiratory and Critical Care Medicine|October 6, 1997
Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study GroupR Hafner, J A Cohn, D J Wright, et al.
The New England Journal of Medicine|April 15, 2000
Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDSW M El-Sadr, W J Burman, L B Grant, et al.
Pageof 8